Oncology - Medicine.net

As cancer deaths decline, access to care remains a challenge in some US communities

by Alex Osiadacz,Mayo ClinicCredit: Unsplash/CC0 Public DomainCancer remains the second-leading cause of death in the U.S., but the number of people dying from cancer continues to decline. In th

Updated on: January 04,2024

9

As cancer deaths decline, access to care remains a challenge in some US communities

by Alex Osiadacz,Mayo ClinicCredit: Unsplash/CC0 Public DomainCancer remains the second-leading cause of death in the U.S., but the number of people dying from cancer continues to decline. In th

Updated on:January 04,2024

9

UGN-101 reviewed in real-world upper tract urothelial cancer setting

by Elana GotkineFor patients with upper tract urothelial cancers (UTUCs), the novel therapeutic UGN-101 seems to be effective, with an acceptable safety profile, according to research published online

Updated on: December 17,2023

6

UGN-101 reviewed in real-world upper tract urothelial cancer setting

by Elana GotkineFor patients with upper tract urothelial cancers (UTUCs), the novel therapeutic UGN-101 seems to be effective, with an acceptable safety profile, according to research published online

Updated on:December 17,2023

6

AI model using daily step counts predicts unplanned hospitalizations during cancer therapy

byAmerican Society for Radiation OncologyCredit: Pixabay/CC0 Public DomainAn artificial intelligence (AI) model developed by researchers can predict the likelihood that a patient may have an unp

Updated on: January 04,2024

9

AI model using daily step counts predicts unplanned hospitalizations during cancer therapy

byAmerican Society for Radiation OncologyCredit: Pixabay/CC0 Public DomainAn artificial intelligence (AI) model developed by researchers can predict the likelihood that a patient may have an unp

Updated on:January 04,2024

9

One-cycle cisplatin seems safe for high-risk early testicular cancer

(HealthDay)—For high-risk stage 1 nonseminoma germ cell tumors of the testis (NSGCTT), one cycle of adjuvant bleomycin, etoposide (500 mg/m²), and cisplatin (BE500P) is safe, resulting in a two-year m

Updated on: December 20,2023

12

One-cycle cisplatin seems safe for high-risk early testicular cancer

(HealthDay)—For high-risk stage 1 nonseminoma germ cell tumors of the testis (NSGCTT), one cycle of adjuvant bleomycin, etoposide (500 mg/m²), and cisplatin (BE500P) is safe, resulting in a two-year m

Updated on:December 20,2023

12

Newfound mechanism suggests drug combination could starve pancreatic cancer

byNYU Langone HealthPancreatic cancer cells (blue) growing as a sphere encased in membranes (red). Credit: National Cancer InstituteA new combination of treatments safely decreased growth of pan

Updated on: October 14,2023

189

Newfound mechanism suggests drug combination could starve pancreatic cancer

byNYU Langone HealthPancreatic cancer cells (blue) growing as a sphere encased in membranes (red). Credit: National Cancer InstituteA new combination of treatments safely decreased growth of pan

Updated on:October 14,2023

189

Camrelizumab Plus Nab-Paclitaxel Showcases Antitumor Activity in Platinum-Resistant Urothelial

September 30, 2022Ryan ScottThe combination of camrelizumab and nab-paclitaxel produced encouraging responses in patients with platinum-resistant, unresectable locally advanced or metastatic urothelia

Updated on: October 17,2023

63

Camrelizumab Plus Nab-Paclitaxel Showcases Antitumor Activity in Platinum-Resistant Urothelial

September 30, 2022Ryan ScottThe combination of camrelizumab and nab-paclitaxel produced encouraging responses in patients with platinum-resistant, unresectable locally advanced or metastatic urothelia

Updated on:October 17,2023

63

WHO moves step closer to cheaper breast cancer treatment

The World Health Organization has approved a biosimilar version of Trastuzumab—the drug used to treat breast cancer—that is generally 65 percent cheaper than the originalThe World Health Organization

Updated on: December 22,2023

16

WHO moves step closer to cheaper breast cancer treatment

The World Health Organization has approved a biosimilar version of Trastuzumab—the drug used to treat breast cancer—that is generally 65 percent cheaper than the originalThe World Health Organization

Updated on:December 22,2023

16

Survival is a mixed matter for deadliest of pancreatic cancers

byUniversity of California - San DiegoPancreatic cancer cells (nuclei in blue) are shown growing as a sphere encased in membranes (red). Credit: National Cancer InstitutePancreatic ductal adenoc

Updated on: December 21,2023

6

Survival is a mixed matter for deadliest of pancreatic cancers

byUniversity of California - San DiegoPancreatic cancer cells (nuclei in blue) are shown growing as a sphere encased in membranes (red). Credit: National Cancer InstitutePancreatic ductal adenoc

Updated on:December 21,2023

6

Targeted therapy drug helps women with aggressive breast cancer live longer

by Denise Heady,University of California, Los AngelesSenior author Dr. Dennis Slamon says “there is absolutely no reason to wait” to give women treatment that combines ribociclib with hormone th

Updated on: December 22,2023

10

Targeted therapy drug helps women with aggressive breast cancer live longer

by Denise Heady,University of California, Los AngelesSenior author Dr. Dennis Slamon says “there is absolutely no reason to wait” to give women treatment that combines ribociclib with hormone th

Updated on:December 22,2023

10

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

At the 2023 American Society for Clinical Oncology Annual Meeting—to be held June 2-6 in Chicago, Illinois—Fred Hutchinson Cancer Center experts will present research spanning survivorship, advances i

Updated on: November 21,2023

17

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

At the 2023 American Society for Clinical Oncology Annual Meeting—to be held June 2-6 in Chicago, Illinois—Fred Hutchinson Cancer Center experts will present research spanning survivorship, advances i

Updated on:November 21,2023

17

Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC

November 15, 2022Kristi RosaThe addition of eganelisib to atezolizumab and nab-paclitaxel demonstrated evidence of a long-term progression-free survival benefit when used as first-line treatment in pa